Oral semaglutide is the same GLP-1 medication found in Ozempic and Wegovy, made into a daily tablet. Because semaglutide is a peptide that stomach acid and enzymes normally break down, the tablet includes an absorption enhancer (SNAC) that helps a small fraction of the dose get into the bloodstream through the stomach wall. That's why oral doses are much larger in milligrams than injected ones, and why the timing rules are strict: take it in the morning on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medicines. Check your own label for the exact instructions.
In the US it is sold for two uses. Rybelsus was approved in 2019 for type 2 diabetes; since May 4, 2026 a reformulated version has been sold in the US as Ozempic tablets (the 4 mg and 9 mg tablets correspond to Rybelsus 7 mg and 14 mg, and the strengths aren't interchangeable mg-for-mg). Ozempic tablets share Rybelsus's label: the same type 2 diabetes and cardiovascular-risk indications, and the same boxed warning about thyroid C-cell tumors seen in rodents (Ozempic tablets and Rybelsus prescribing information (external link)). The Wegovy pill (oral semaglutide 25 mg) was approved on December 22, 2025 as the first oral GLP-1 for chronic weight management; in the OASIS 4 trial it produced weight loss similar to injectable Wegovy. See comparing the GLP-1 pills, the history of GLP-1 medications and manufacturer savings cards.